GeneDx Holdings Corp (NASDAQ: WGS) Chief Financial Officer Kevin Feeley completed a sale of 5,706 shares of Class A common stock on March 16, 2026, at transaction prices that ranged from $76.3492 to $77.9354. Proceeds from those sales totaled approximately $438,202.
The share sales followed the exercise of equity awards. On March 15 and March 16, 2026, Feeley exercised options to acquire 11,012 shares of Class A common stock at an exercise price of $0.
After settling the option exercise and the subsequent disposition of shares, Feeley directly holds 27,148 shares of GeneDx. He also retains rights to acquire another 109,423 shares through restricted stock units and holds options to purchase an additional 25,906 shares.
Market sentiment toward the stock has been soft in the short term. The shares have fallen about 15% over the past week and trade roughly 56% below their 52-week high of $170.87.
At a reported market price of $75.50, an external analysis included in company research indicates the stock appears undervalued and assigns a "GOOD" score for financial health. That analysis is accompanied by a Pro Research Report cited as a source for deeper valuation and analyst guidance.
GeneDx also released fourth-quarter results that were mixed. Revenue for the quarter came in at $121.0 million, a 27% increase year-over-year that slightly exceeded analyst estimates. However, the company missed on earnings, a shortfall that weighed on pre-market sentiment.
Following the quarter, several sell-side analysts reiterated positive ratings. Canaccord Genuity maintained a Buy rating and left a $170 price target in place. TD Cowen also reiterated a Buy view, highlighting revenue drivers expected in fiscal 2026, including growth from geneticists and pediatric neurologists. BTIG adjusted its price target to $170 from $200, while keeping a Buy rating, noting an expectation of back-end loaded growth.
Competition is a contextual factor for GeneDx. Natera introduced a competing test called Zenith genomics aimed at rare disease diagnosis, a development noted as material to GeneDx's competitive landscape.
These transactions and corporate developments present a mix of signals - executive liquidity following a zero-cost option exercise, a near-term stock drawdown, revenue outperformance, an earnings miss, reaffirmed analyst endorsements, and a newly announced competitor test - all occurring within the same reporting period.